L. Ley

发表

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer A C

S. Steinberg, Yipeng Wang, J. Trepel, 2021 .

A pilot study of molecularly tailored therapy for patients with metastatic pancreatic cancer (MPC).

J. Marshall, L. Weiner, Hongkun Wang, 2015 .

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

S. Steinberg, H. Parnes, J. Trepel, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

S. Steinberg, Yipeng Wang, J. Trepel, 2020, Clinical Cancer Research.

Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer

J. Marshall, A. Wellstein, L. Weiner, 2016, Oncology letters.

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

S. Steinberg, H. Parnes, M. Merino, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer

J. Marshall, L. Weiner, M. Pishvaian, 2015, Cancer Chemotherapy and Pharmacology.

Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety

J. Marshall, M. Pishvaian, G. Tse, 2013, Radiation oncology.

A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC).

J. Marshall, L. Weiner, Hongkun Wang, 2013 .

Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC).

J. Marshall, L. Weiner, Hongkun Wang, 2019, Journal of Clinical Oncology.

Human Pancreatic Cancer-Associated Stellate Cells Remain Activated after in vivo Chemoradiation

T. Schroeder, M. C. Cabrera, M. Pishvaian, 2014, Front. Oncol..

A phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil and oxaliplatin (modified FOLFOX-6) in patients with metastatic pancreatic cancer.

J. Marshall, L. Weiner, M. Pishvaian, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.